Skip to content
Universidad del Mar SIBUMAR Descubridor Institucional UMAR
  • Inicio
  • Búsqueda avanzada
  • Explorar
  • Login
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
Advanced
  • Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study
Cover Image

Treatment Effectiveness of Venetoclax‐Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real‐World Study

Fuente: Wiley Open Access
Saved in:
Bibliographic Details
Main Authors: Nilanjan Ghosh, Toby A. Eyre, Jennifer R. Brown, Nicole Lamanna, Beenish S. Manzoor, Catherine C. Coombs, Hande H. Tuncer, Chaitra Ujjani, Lori A. Leslie, Lindsey E. Roeker, Matthew S. Davids, Joanna M. Rhodes, Alan P. Skarbnik, Wendy Sinai, Isabelle Fleury, Brian T. Hill, Nicolas Martinez‐Calle, Paul M. Barr, Dureshahwar Jawaid, Nnadozie Emechebe, Laurie Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Bita Fakhri, Deborah M. Stephens, Steven E. Marx, Stephen J. Schuster, Michael Coyle, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Format: Artículo Open Access
Published: Wiley 2024
Subjects:
American Journal of Hematology
Online Access:
Acceder al recurso
Tags: Add Tag
No Tags, Be the first to tag this record!
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Save to List
  • Permanent link
  • Holdings
  • Description
  • Comments
  • Similar Items
  • Staff View
Be the first to leave a comment!
You must be logged in first

Similar Items

  • Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia
    by: Nilanjan Ghosh, et al.
    Published: (2024)
  • 610 | RELATIVE EFFICACY OF VENETOCLAX PLUS IBRUTINIB VERSUS BRUTON TYROSINE KINASE INHIBITOR MONOTHERAPY AND CHEMOIMMUNOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    by: N. Ghosh, et al.
    Published: (2025)
  • Long‐term follow‐up of dose‐dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second‐line treatment of relapsed/refractory classical Hodgkin lymphoma
    by: Ryan C. Lynch, et al.
    Published: (2025)
  • Measurable residual disease‐driven treatment in first‐line chronic lymphocytic leukaemia
    by: M. S. Davids, et al.
    Published: (2024)
  • Bridging Logic Programming and Deep Learning for Explainability through ILASP
    by: Dreossi, Talissa
    Published: (2025)
Universidad del Mar
Universidad del MarSistema Bibliotecario de la Universidad del MarDescubridor Institucional UMARImplementación y desarrollo: Mtro. Carlos Alonso Albores Pérez
InicioBúsqueda avanzadaExplorar
Visitas al Descubridor: 387,319© 2026 Universidad del Mar